Gainers
- Akero Therapeutics, Inc. (NASDAQ:AKRO) shares jumped 136.8% to settle at $29.05 on Tuesday after the company's Phase 2b HARMONY study met its primary endpoint for both the 50mg and 28mg EFX dose groups.
- Aditxt, Inc. (NASDAQ:ADTX) jumped 113.8% to close at $0.37.
- Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA) surged 101% to close at $3.86 after a late Monday Form 4 filing showed multiple insider purchases of the stock.
- NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) climbed 79.3% to close at $29.90 on Tuesday as the stock started trading on a 1-for-30 reverse split basis.
- 89bio, Inc. (NASDAQ:ETNB) shares rose 40% to close at $7.00. Analysts reportedly said Akero's NASH data could be a positive for the company's Pegoza program in NASH.
- Motorsport Games Inc. (NASDAQ:MSGM) climbed 28.1% to close at $0.97. Motorsport Games, last month, reported worse-than-expected Q2 EPS results.
- Akouos, Inc. (NASDAQ:AKUS) gained 28% to close at $4.48. The FDA has signed off Akouos Investigational New Drug application to initiate a Phase 1/2 trial of AK-OTOF, gene therapy for otoferlin gene (OTOF)-mediated hearing loss.
- Infobird Co., Ltd (NASDAQ:IFBD) jumped 28% to settle at $2.47.
- Golden Path Acquisition Corporation (NASDAQ:GPCO) rose 22.4% to settle at $8.69.
- Ensysce Biosciences, Inc. (NASDAQ:ENSC) gained 22.3% to close at $0.4131.
- Immuneering Corporation (NASDAQ:IMRX) jumped 22.1% to close at $12.00. Immuneering recently submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for its product candidate IMM-1-104 in development for the treatment of advanced RAS mutant solid tumors.
- Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) rose 21% to close at $0.2299.
- VNET Group, Inc. (NASDAQ:VNET) gained 20.7% to close at $5.66 after the company announced the receipt of a preliminary non-binding proposal to acquire all of its shares and formation of a special committee to review the proposal.
- Cosmos Holdings Inc. (NASDAQ:COSM) climbed 19.7% to settle at $0.4216. Cosmos Health’s subsidiary SkyPharm recently launched its first Sky Premium Life products on Amazon in the U.S.
- Palisade Bio, Inc. (NASDAQ:PALI) jumped 18.3% to settle at $0.1782. Palisade Bio was Granted U.S. patent titled 'Administration of serine protease inhibitors to the stomach.'
- Aprea Therapeutics, Inc. (NASDAQ:APRE) gained 17.7% to close at $0.9299.
- Phunware, Inc. (NASDAQ:PHUN) surged 15.6% to settle at $1.63.
- NLS Pharmaceutics AG (NASDAQ:NLSP) gained 14.2% to close at $1.12. Laidlaw & Co. recently initiated coverage on NLS Pharmaceutics with a Buy rating and announced a price target of $6.
- iBio, Inc. (NYSE:IBIO) rose 13.7% to close at $0.3080 after declining over 4% on Monday.
- Planet Labs PBC (NYSE:PL) gained 13.5% to close at $6.15 after the company reported better-than-expected Q2 results and raised guidance.
- Aehr Test Systems (NASDAQ:AEHR) gained 13.5% to close at $15.99 after the company received a wafer level burn-in system order.
- HilleVax, Inc. (NASDAQ:HLVX) rose 12.4% to close at $22.01.
- Hycroft Mining Holding Corporation (NASDAQ:HYMC) rose 12.1% to close at $0.8914. The company earlier reported initial drill results from its 2022-2023 exploration program.
- Entrada Therapeutics, Inc. (NASDAQ:TRDA) surged 10.3% to settle at $13.14.
- Tyme Technologies, Inc. (NASDAQ:TYME) gained 9.1% to close at $0.2807 after gaining around 4% on Monday.
- V2X, Inc. (NYSE:VVX) gained 8.6% to close at $41.25.
- LSB Industries, Inc. (NYSE:LXU) gained 6.3% to close at $17.04. Piper Sandler initiated coverage on LSB Industries with an Overweight rating and announced a price target of $26.
- Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) shares rose 4.9% to close at $0.7659 after the FDA granted Syros Pharmaceuticals Orphan Drug Designation for the treatment of pancreatic cancer.
- Core & Main, Inc. (NYSE:CNM) rose 2.5% to close at $25.11 following upbeat Q2 results.
